Abstract: The present invention aims to develop a method for treating COVID-19 caused by SARS-CoV-2 or a mutant strain thereof, and provides an agent for preventing and/or treating COVID-19 caused by SARS-CoV-2 or a mutant strain thereof, the agent comprising a specific compound.

Abstract: A therapeutic agent for a corneal epithelial disorder, containing a miR-203 inhibitor; an agent for promoting proliferation of corneal epithelial cells, containing a miR-203 inhibitor; a liquid culture medium for use in the manufacture of a corneal epithelial sheet, containing a miR-203 inhibitor; and a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using a liquid culture medium containing a miR-203 inhibitor. According to the present invention, a therapeutic agent for a corneal epithelial disorder, an agent for promoting proliferation of corneal epithelial cells, a liquid culture medium for use in the manufacture of a corneal epithelial sheet, a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using the liquid culture medium, and a method for treating a corneal epithelial disorder can be provided.

Abstract: A therapeutic agent for a corneal epithelial disorder, containing a miR-203 inhibitor; an agent for promoting proliferation of corneal epithelial cells, containing a miR-203 inhibitor; a liquid culture medium for use in the manufacture of a corneal epithelial sheet, containing a miR-203 inhibitor; and a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using a liquid culture medium containing a miR-203 inhibitor. According to the present invention, a therapeutic agent for a corneal epithelial disorder, an agent for promoting proliferation of corneal epithelial cells, a liquid culture medium for use in the manufacture of a corneal epithelial sheet, a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using the liquid culture medium, and a method for treating a corneal epithelial disorder can be provided.

Abstract: The invention provides an agent for promoting ocular tissue neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof, and an agent for promoting corneal neuritogenesis and retinal neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof. The corneal neuritogenesis promoter can be used for the improvement of corneal sensitivity, treatment of dry eye, or treatment of a corneal epithelial disorder. The retinal neuritogenesis promoter can be used for the improvement of a visual dysfunction.

Abstract: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.

Abstract: The invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, which is a particular partial sequence of lacritin, and having an amino acid length of not more than 70 residues. The polypeptide of the invention can promote adhesion between a cell and an extracellular matrix, and can promote tear fluid secretion from lacrimal gland acinar cells.

Abstract: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.

Abstract: Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1? expression and a substance specifically inhibiting HIF-2? expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1? and HIF-2?, or expression vectors thereof.

Abstract: Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1? expression and a substance specifically inhibiting HIF-2? expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1? and HIF-2?, or expression vectors thereof.

Abstract: It is intended to provide an agent for promoting corneal neuritogenesis containing PACAP, a PACAP derivative or a pharmaceutically acceptable salt thereof, in particular, an agent for promoting corneal neuritogenesis aiming at improving corneal sensitivity, treating dry eye and treating corneal epithelial injury due to an effect of promoting corneal neuritogenesis. This agent for promoting corneal neuritogenesis is useful as a drug for ameliorating reduction in corneal sensitivity following corneal surgeries such as laser keratonomy (LASIK) and corneal grafting or cataract surgery, reduction in corneal sensitivity accompanying corneal neurodegeneration and dry eye symptom and corneal epithelial injury accompanying such reduction in corneal sensitivity.

Abstract: The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye.

Abstract: The invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, which is a particular partial sequence of lacritin, and having an amino acid length of not more than 70 residues. The polypeptide of the invention can promote adhesion between a cell and an extracellular matrix, and can promote tear fluid secretion from lacrimal gland acinar cells.

Abstract: The present invention relates to a means that allows supplying lacritin stably and in large amounts, and provides a vector containing polynucleotide that encodes lacritin, wherein said nucleotide is operatively linked to a cytomegalovirus immediate early enhancer/promoter and an SV40 late polyA signal, a lacritin-expressing cell prepared by introducing the vector into a cell, a method of producing recombinant lacritin, including the step of culturing the lacritin-expressing cell in a medium, and the step of isolating lacritin in the culture supernatant, and an agent for treating ocular disease containing the lacritin-expressing cell.

Abstract: The invention provides an agent for promoting ocular tissue neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof, and an agent for promoting corneal neuritogenesis and retinal neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof. The corneal neuritogenesis promoter can be used for the improvement of corneal sensitivity, treatment of dry eye, or treatment of a corneal epithelial disorder. The retinal neuritogenesis promoter can be used for the improvement of a visual dysfunction.

Abstract: The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye.

Abstract: The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye.

Abstract: The present invention provides a novel pharmaceutical agent for recovering corneal sensitivity after corneal surgery and improving symptoms of dry eye. This pharmaceutical agent is useful for improving decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as post-cataract operation, post-LASIK operation, post-PRK operation, postkeratoplasty operation, neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy and the like, since it contains a Rho protein inhibitor.

Abstract: The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye.

Abstract: The present invention provides a new type of pharmaceutical agent that recovers corneal sensitivity after corneal surgery or improves the condition of dry eye. Application of a somatostatin receptor agonist is expected to provide an improvement effect on decreased corneal sensitivity after cataract surgery or LASIK surgery, decreased corneal sensitivity and dry eye associated with corneal neurodegeneration such as neuroparalytic keratopathy, corneal ulcer, diabetic keratopathy and the like.

Abstract: An agent for the prophylaxis and treatment of glaucoma, which contains a compound having a Rho kinase inhibitory activity, particularly an agent for the prophylaxis and treatment of glaucoma, which contains a compound of the formula (I) wherein each symbol is as defined in the specification, as the compound having a Rho kinase inhibitory activity, is provided. The agent for the prophylaxis and treatment of glaucoma of the present invention is a novel agent for the prophylaxis and treatment of glaucoma and has intraocular pressure lowering action, optic disc blood flow improving action and aqueous humor outflow promoting action.